Scarica l'app Stockscreener
29.00
2.62%
-0.78
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché GMAB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$29.78
Aprire:
$29.23
Volume 24 ore:
4.93M
Relative Volume:
2.55
Capitalizzazione di mercato:
$17.80B
Reddito:
$3.91B
Utile/perdita netta:
$823.88M
Rapporto P/E:
21.87
EPS:
1.3262
Flusso di cassa netto:
$875.28M
1 W Prestazione:
+1.70%
1M Prestazione:
+18.42%
6M Prestazione:
-15.35%
1 anno Prestazione:
+32.66%
Intervallo 1D:
$28.36
$29.45
Intervallo di 1 settimana:
$27.63
$29.80
Portata 52W:
$21.00
$35.43
Genmab Adr Stock (GMAB) Company Profile
Compare GMAB vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GMAB
Genmab Adr
|
29.00 | 17.80B | 3.91B | 823.88M | 875.28M | 1.3262 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-22 | Aggiornamento | Goldman | Neutral → Buy |
| 2026-03-27 | Iniziato | Wolfe Research | Outperform |
| 2026-03-02 | Iniziato | Wells Fargo | Overweight |
| 2026-02-17 | Ripresa | Jefferies | Buy |
| 2026-02-17 | Ripresa | Morgan Stanley | Equal-Weight |
| 2025-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-04-01 | Downgrade | Bernstein | Mkt Perform → Underperform |
| 2025-03-11 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2025-02-13 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-08 | Iniziato | Redburn Atlantic | Buy |
| 2024-09-04 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-08-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-15 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-02-23 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2024-01-22 | Downgrade | Citigroup | Neutral → Sell |
| 2023-12-06 | Aggiornamento | UBS | Neutral → Buy |
| 2023-11-10 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2023-11-08 | Aggiornamento | DNB Markets | Sell → Buy |
| 2023-10-18 | Iniziato | Exane BNP Paribas | Underperform |
| 2023-09-06 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-24 | Iniziato | BTIG Research | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-31 | Iniziato | UBS | Neutral |
| 2023-05-12 | Iniziato | Morgan Stanley | Underweight |
| 2022-12-20 | Downgrade | Citigroup | Buy → Neutral |
| 2022-11-14 | Iniziato | William Blair | Mkt Perform |
| 2022-11-11 | Downgrade | Deutsche Bank | Buy → Hold |
| 2022-06-24 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-05-02 | Iniziato | Cowen | Market Perform |
| 2022-03-16 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-31 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-12-01 | Iniziato | Berenberg | Sell |
| 2021-09-16 | Downgrade | Jefferies | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-08-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-04-20 | Iniziato | Deutsche Bank | Buy |
| 2021-01-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-09-23 | Downgrade | Bryan Garnier | Neutral → Sell |
| 2020-09-08 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-06-25 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2020-04-23 | Iniziato | Credit Suisse | Outperform |
| 2020-02-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-12-12 | Downgrade | Deutsche Bank | Buy → Hold |
| 2019-09-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-09-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-08-12 | Iniziato | Guggenheim | Buy |
| 2019-08-12 | Iniziato | Morgan Stanley | Overweight |
| 2019-08-12 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Genmab Adr Borsa (GMAB) Ultime notizie
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma - TradingView
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma - GlobeNewswire Inc.
GMABGenmab ADR Earnings - Finviz
Amazon To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Thursday - Sahm
Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity - Sahm
Genmab (GMAB) Shows Modest Gains Amid Consolidation: Support and Resistance Levels in FocusSector Neutral Pair - dars.gov.et
Genmab A/S Sponsored ADR Actuals & Estimates (NASDAQ:GMAB) - TradingView
GE91 Forecast — Price Target — Prediction for 2027 - TradingView
GMAB1/N Forecast — Price Target — Prediction for 2027 - TradingView
GMAB News | GENMAB A/S -SP ADR (NASDAQ:GMAB) - ChartMill
Genmab A/S stock (DK0010272202): Copenhagen shares weaken as investors weigh outlook after updated A - AD HOC NEWS
GMAB Q1 2026 Earnings: EPS Misses Estimates by Over 40% as Stock DeclinesQuarterly Earnings Report - The Legal Advocate
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Crescent Biopharma (CBIO) and Genmab (GMAB) - The Globe and Mail
GMAB Stock Price, Quote & Chart | GENMAB A/S -SP ADR (NASDAQ:GMAB) - ChartMill
GMAB vs. ACAD: Which Stock Is the Better Value Option? - MSN
Genmab A/S stock (DK0010272202): earnings momentum and oncology pipeline keep investors watching - AD HOC NEWS
Genmab stock (DK0010272202): Analyst sentiment shifts as earnings forecasts decline - AD HOC NEWS
Genmab Earnings: Strong Patient Uptake and Diverse Late-Stage Pipeline Support Positive Outlook - Morningstar
Genmab A/S Q1 Earnings Call Highlights - Yahoo Finance
Oppenheimer Asset Management Inc. Acquires 48,894 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
Pictet Asset Management Holding SA Takes $33.84 Million Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab ADR shows improved relative strength; still shy of benchmark - MSN
BioNTech (BNTX) surges 6.1%: Is this an indication of further gains? - MSN
BioNTech (BNTX) Surges 6.1%: Is This an Indication of Further Gains? - Yahoo Finance
Bispecific Antibody Drug Conjugates Market Landscape Report 2026: A $2 Billion Opportunity by 2030 with the 1st Approved BsADC by 2028 - GlobeNewswire Inc.
Bispecific Antibody Market Landscape Report 2026: A Potential $60 Opportunity by 2031Insight on More than 550 Clinical Trials - GlobeNewswire Inc.
Genmab A/S (NASDAQ:GMAB) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Genmab A/S Sponsored ADR $GMAB Shares Bought by Assetmark Inc. - MarketBeat
Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge - Sahm
827,217 Shares in Genmab A/S Sponsored ADR $GMAB Bought by Perpetual Ltd - marketbeat.com
JPMorgan Chase & Co. Decreases Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Arrowpoint Investment Partners Singapore Pte. Ltd. Takes Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab AS (ADR) (US3723032062.SG) Q1 FY2025 earnings call transcript - Yahoo Finance
Terra Nova Asset Management LLC Invests $1.87 Million in Genmab A/S Sponsored ADR $GMAB - MarketBeat
This Honeywell Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Genmab A/S Touts Strong 2025, Teases Catalyst-Heavy 2026 With Potential 2027 Launches - Yahoo Finance
Alliancebernstein L.P. Has $335.96 Million Stock Holdings in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Genmab A/ S: The Biotech Stock Gen Z Is Quietly Watching - AD HOC NEWS
Russell Investments Group Ltd. Has $25.23 Million Holdings in Genmab A/S Sponsored ADR $GMAB - MarketBeat
First Trust Advisors LP Sells 82,922 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
GMAB Earnings History & Surprises | EPS & Revenue Results | GENMAB A/S -SP ADR (NASDAQ:GMAB) - ChartMill
Genmab (GMAB) Upgraded to Strong Buy: Here's Why - MSN
Genmab A/S -SP ADR (NASDAQ:GMAB) Presents a Compelling Value Investment Case - ChartMill
Genmab Adr Azioni (GMAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Genmab Adr Azioni (GMAB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| GENMAB A/S | 10% Owner |
Dec 26 '25 |
Buy |
97.00 |
2,978 |
288,866 |
72,831,487 |
| GENMAB A/S | 10% Owner |
Dec 23 '25 |
Buy |
97.00 |
561,042 |
54,421,074 |
72,589,817 |
| GENMAB A/S | 10% Owner |
Dec 26 '25 |
Buy |
97.00 |
142,610 |
13,833,170 |
72,828,509 |
| GENMAB A/S | 10% Owner |
Dec 24 '25 |
Buy |
97.00 |
96,082 |
9,319,954 |
72,685,899 |
| GENMAB A/S | 10% Owner |
Dec 22 '25 |
Buy |
97.00 |
15,710 |
1,523,870 |
72,028,775 |
| GENMAB A/S | 10% Owner |
Dec 18 '25 |
Buy |
97.00 |
212,177 |
20,581,169 |
71,946,801 |
| GENMAB A/S | 10% Owner |
Dec 19 '25 |
Buy |
97.00 |
66,264 |
6,427,608 |
72,013,065 |
| GENMAB A/S | 10% Owner |
Dec 17 '25 |
Buy |
97.00 |
150,795 |
14,627,115 |
71,734,624 |
| GENMAB A/S | 10% Owner |
Dec 16 '25 |
Buy |
97.00 |
120,752 |
11,712,944 |
71,583,829 |
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):